|
Market Closed -
Nasdaq
01:30:00 16/07/2026 am IST
|
5-day change
|
1st Jan Change
|
|
4.210 USD
|
+3.95%
|
 |
+4.21%
|
-23.01%
|
|
13/05 |
Bolt Biotherapeutics reports first quarter 2026 financial results
|
RE
| |
13/05 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
13/03 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
13/11 |
Bolt Biotherapeutics Q3 collaboration revenue doubles
|
RE
| |
13/11 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
| |
03/25/03 |
Bolt Biotherapeutics, Inc. Provides Update on Ongoing Phase 1 Dose Escalation Study of BDC-4182
|
CI
| |
15/25/15 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
|
CI
| |
13/25/13 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
|
CI
| |
01/25/01 |
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody ISACs Targeting Cea and PD-L1 At AACR Annual Meeting 2025
|
CI
| |
25/25/25 |
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 At AACR Annual Meeting 2025
|
CI
| |
25/25/25 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024
|
CI
| |
25/25/25 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024
|
CI
| |
12/25/12 |
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc
|
CI
| |
13/24/13 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
|
CI
| |
07/24/07 |
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
|
CI
| |
14/24/14 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
|
CI
| |
15/24/15 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
|
CI
| |
22/24/22 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
|
CI
| |
22/24/22 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
|
CI
| |
05/23/05 |
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu
|
CI
| |
10/23/10 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
|
CI
| |
23/23/23 |
Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
|
CI
| |
28/23/28 |
Bolt Biotherapeutics Says US FDA Granted Orphan Drug Designation for BDC-1001 for Gastric Cancer
|
MT
| |
08/23/08 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
|
CI
| |
12/23/12 |
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
|
CI
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
Choose MarketScreener 
